Literature DB >> 34624435

DIP: Natural history model for major depression with incidence and prevalence.

Melike Yildirim1, Bradley N Gaynes2, Pinar Keskinocak3, Brian W Pence4, Julie Swann5.   

Abstract

BACKGROUND: Major depression is a treatable disease, and untreated depression can lead to serious health complications. Therefore, prevention, early identification, and treatment efforts are essential. Natural history models can be utilized to make informed decisions about interventions and treatments of major depression.
METHODS: We propose a natural history model of major depression. We use steady-state analysis to study the discrete-time Markov chain model. For this purpose, we solved the system of linear equations and tested the parameter and transition probabilities empirically.
RESULTS: We showed that bias in parameters might collectively cause a significant mismatch in a model. If incidence is correct, then lifetime prevalence is 33.2% for females and 20.5% for males, which is higher than reported values. If prevalence is correct, then incidence is .0008 for females and .00065 for males, which is lower than reported values. The model can achieve feasibility if incidence is at low levels and recall bias of the lifetime prevalence is quantified to be 31.9% for females and 16.3% for males. LIMITATIONS: This model is limited to major depression, and patients who have other types of depression are assumed healthy. We assume that transition probabilities (except incidence rates) are correct.
CONCLUSION: We constructed a preliminary model for the natural history of major depression. We determined the lifetime prevalences are underestimated and the average incidence rates may be underestimated for males. We conclude that recall bias needs to be accounted for in modeling or burden estimates, where the recall bias should increase with age.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Incidence; Lifetime prevalence; Major depression; Natural history; Prevalence; Recall bias

Mesh:

Year:  2021        PMID: 34624435     DOI: 10.1016/j.jad.2021.09.079

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  1 in total

1.  Cost-Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective.

Authors:  Andrea Carta; Maria Del Zompo; Anna Meloni; Francesco Mola; Pasquale Paribello; Federica Pinna; Marco Pinna; Claudia Pisanu; Mirko Manchia; Alessio Squassina; Bernardo Carpiniello; Claudio Conversano
Journal:  Clin Drug Investig       Date:  2022-08-05       Impact factor: 3.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.